Literature DB >> 22936467

What should we expect in a prognosis study in 2012?

Rory Hachamovitch.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22936467     DOI: 10.1007/s12350-012-9611-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  15 in total

Review 1.  Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be?

Authors:  Leslee J Shaw; Fadi G Hage; Daniel S Berman; Rory Hachamovitch; Ami Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

2.  Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?

Authors:  Rory Hachamovitch; Alan Rozanski; Sean W Hayes; Louise E J Thomson; Guido Germano; John D Friedman; Ishac Cohen; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

Review 3.  Methods and limitations of assessing new noninvasive tests: Part II: Outcomes-based validation and reliability assessment of noninvasive testing.

Authors:  Rory Hachamovitch; Marcelo F Di Carli
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

Review 4.  Methods and limitations of assessing new noninvasive tests: part I: Anatomy-based validation of noninvasive testing.

Authors:  Rory Hachamovitch; Marcelo F Di Carli
Journal:  Circulation       Date:  2008-05-20       Impact factor: 29.690

Review 5.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

6.  Modeling and variable selection in epidemiologic analysis.

Authors:  S Greenland
Journal:  Am J Public Health       Date:  1989-03       Impact factor: 9.308

7.  Prognostic indicators from radionuclide angiography in medically treated patients with coronary artery disease.

Authors:  D B Pryor; F E Harrell; K L Lee; R A Rosati; R E Coleman; F R Cobb; R M Califf; R H Jones
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

8.  Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness.

Authors:  Rory Hachamovitch; Daniel S Berman; Hosen Kiat; Ishac Cohen; John D Friedman; Leslee J Shaw
Journal:  Circulation       Date:  2002-02-19       Impact factor: 29.690

9.  Regression models for prognostic prediction: advantages, problems, and suggested solutions.

Authors:  F E Harrell; K L Lee; D B Matchar; T A Reichert
Journal:  Cancer Treat Rep       Date:  1985-10

10.  Is there a referral bias against catheterization of patients with reduced left ventricular ejection fraction? Influence of ejection fraction and inducible ischemia on post-single-photon emission computed tomography management of patients without a history of coronary artery disease.

Authors:  Rory Hachamovitch; Sean W Hayes; John D Friedman; Ishac Cohen; Xingping Kang; Guido Germano; Daniel S Berman
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

View more
  2 in total

1.  Immortality time and serial myocardial perfusion imaging: Only those who do not die may repeat the exam.

Authors:  Mario Petretta; Marco Salvatore; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2015-05-14       Impact factor: 5.952

2.  Prognosis in patients with suspected or known ischemic heart disease and normal myocardial perfusion: long-term outcome and temporal risk variations.

Authors:  Jane A Simonsen; Oke Gerke; Charlotte K Rask; Mohammad Tamadoni; Anders Thomassen; Søren Hess; Allan Johansen; Hans Mickley; Lisette O Jensen; Jesper Hallas; Werner Vach; Poul F Høilund-Carlsen
Journal:  J Nucl Cardiol       Date:  2013-03-01       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.